Business Description
Arcutis Biotherapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US03969K1088
Share Class Description:
ARQT: Ordinary SharesTotal Employee Number:
354Description
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 2.09 | |||||
Equity-to-Asset | 0.45 | |||||
Debt-to-Equity | 0.52 | |||||
Debt-to-EBITDA | 2.51 | |||||
Interest Coverage | 2.47 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 5.45 | |||||
Beneish M-Score | -1.95 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 253.4 | |||||
3-Year EPS without NRI Growth Rate | 71.6 | |||||
3-Year FCF Growth Rate | 70.7 | |||||
3-Year Book Growth Rate | -23.5 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 29.9 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 39.06 | |||||
9-Day RSI | 37.75 | |||||
14-Day RSI | 39.25 | |||||
3-1 Month Momentum % | 10.97 | |||||
6-1 Month Momentum % | 1.89 | |||||
12-1 Month Momentum % | 41.05 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.92 | |||||
Quick Ratio | 2.67 | |||||
Cash Ratio | 1.49 | |||||
Days Inventory | 244.51 | |||||
Days Sales Outstanding | 105.03 | |||||
Days Payable | 103.57 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -26.4 | |||||
Shareholder Yield % | 0.69 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 91.14 | |||||
Operating Margin % | 7.38 | |||||
Net Margin % | 6.15 | |||||
EBITDA Margin % | 9.78 | |||||
FCF Margin % | 8.47 | |||||
OCF Margin % | 8.47 | |||||
ROE % | 15.9 | |||||
ROA % | 6.77 | |||||
ROIC % | 34.93 | |||||
3-Year ROIIC % | 375.06 | |||||
ROC (Joel Greenblatt) % | 67.56 | |||||
ROCE % | 14.9 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 113.79 | |||||
Forward PE Ratio | 18.47 | |||||
PE Ratio without NRI | 113.79 | |||||
PS Ratio | 6.64 | |||||
PB Ratio | 13.32 | |||||
Price-to-Tangible-Book | 14.21 | |||||
Price-to-Free-Cash-Flow | 77.91 | |||||
Price-to-Operating-Cash-Flow | 77.91 | |||||
EV-to-EBIT | 65.4 | |||||
EV-to-EBITDA | 62.16 | |||||
EV-to-Revenue | 6.08 | |||||
EV-to-Forward-Revenue | 4.39 | |||||
EV-to-FCF | 71.79 | |||||
Price-to-GF-Value | 0.76 | |||||
Price-to-Graham-Number | 8.49 | |||||
| Price-to-Net-Current-Asset-Value | 14.74 | |||||
Earnings Yield (Greenblatt) % | 1.53 | |||||
FCF Yield % | 1.33 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ARQT
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Arcutis Biotherapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 463.981 | ||
| EPS (TTM) ($) | 0.206 | ||
| Beta | 2.1068 | ||
| 3-Year Sharpe Ratio | 0.74 | ||
| 3-Year Sortino Ratio | 1.59 | ||
| Volatility % | 55.85 | ||
| 14-Day RSI | 39.25 | ||
| 14-Day ATR ($) | 0.97377 | ||
| 20-Day SMA ($) | 24.906 | ||
| 12-1 Month Momentum % | 41.05 | ||
| 52-Week Range ($) | 16.57 - 31.77 | ||
| Shares Outstanding (Mil) | 125.69 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Arcutis Biotherapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Arcutis Biotherapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Fourth quarter earnings conference call for 2026 | 2027-02-25 16:30 | In 169 days | ||
| Annual report for 2026 | 2027-02-25 | In 168 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-25 | In 168 days | ||
| Third quarter earnings conference call for 2026 | 2026-10-28 10:30 | In 49 days | ||
| Third quarter earnings results for 2026 | 2026-10-28 | In 48 days | ||
| Morgan Stanley 24th Annual Global Healthcare Conference | 2026-09-16 13:50 | In 7 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-05 16:30 | 26.03 (-0.15%) | ||
| Second quarter earnings results for 2026 | 2026-08-05 | 26.03 (-0.15%) | ||
| Goldman Sachs 47th Annual Global Healthcare Conference, | 2026-06-09 14:00 | 21.54 (+0.42%) | ||
| General meeting for 2026 | 2026-06-05 07:30 | 21.95 (+2.38%) |
Show
Entries
Arcutis Biotherapeutics Inc Frequently Asked Questions
What is Arcutis Biotherapeutics Inc(ARQT)'s stock price today?
The current price of ARQT is $23.44. The 52 week high of ARQT is $31.77 and 52 week low is $16.57.
When is next earnings date of Arcutis Biotherapeutics Inc(ARQT)?
The next earnings date of Arcutis Biotherapeutics Inc(ARQT) is 2026-10-28 Est..
Does Arcutis Biotherapeutics Inc(ARQT) pay dividends? If so, how much?
Arcutis Biotherapeutics Inc(ARQT) does not pay dividend.
Guru Commentaries on NAS:ARQT
AMG GW&K Small Cap Core Fund
Bullish
2025 Q1
AMG GW&K Small Cap Core Fund
· 91 holdings
What the manager wrote
In health care, stock selection in Biotech was extremely strong, led by Halozyme, SpringWorks, Insmed, and Arcutis. The Fund's allocation towards higher quality added approximately 75 bps to relative return, indicating a positive outlook on these holdings. Arcutis, in particular, has been highlighted as a strong contributor, suggesting confidence in its growth potential and market position within the biotech sector.
Press Release
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers